Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TECX
stocks logo

TECX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is 85.00 USD with a low forecast of 76.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is 85.00 USD with a low forecast of 76.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.980
sliders
Low
76.00
Averages
85.00
High
101.00
Current: 20.980
sliders
Low
76.00
Averages
85.00
High
101.00
Oppenheimer
Outperform
initiated
$80
2025-09-03
Reason
Oppenheimer
Price Target
$80
2025-09-03
initiated
Outperform
Reason
Oppenheimer initiated coverage of Tectonic Therapeutic with an Outperform rating and $80 price target. The firm likes the prospects of the company's lead asset TX45 to address prevalent and progressive cardiovascular disorders that are inadequately treated. The analyst is optimistic ahead of next year's Phase 2 readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way to multi-billion global sales opportunity.
Truist
initiated
$64
2025-07-21
Reason
Truist
Price Target
$64
2025-07-21
initiated
Reason
Truist initiated coverage of Tectonic Therapeutic with a Buy rating and $64 price target. Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction and Truist is cautiously optimistic that TX45 will be successful in its ongoing Phase 2 study, the analyst tells investors in a research note. Truist likes the current risk-reward.
Raymond James
Outperform
initiated
$76
2025-06-10
Reason
Raymond James
Price Target
$76
2025-06-10
initiated
Outperform
Reason
Raymond James resumed coverage of Tectonic Therapeutic with an Outperform rating and $76 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm contends that its lead asset, TX45 offers among the most compelling risk/reward propositions within a biotech landscape currently awash with suppressed valuations and favorable skew, Raymond James added. The firm notes that the ongoing Phase 2 targets a high unmet need indication which favorably aligns with relaxin's multi-modal mechanism of action.
LifeSci Capital
Outperform
initiated
$87
2025-06-05
Reason
LifeSci Capital
Price Target
$87
2025-06-05
initiated
Outperform
Reason
LifeSci Capital initiated coverage of Tectonic Therapeutic with an Outperform rating and $87 price target.
Mizuho
Uy Ear
Outperform
maintain
$51 -> $85
2025-05-15
Reason
Mizuho
Uy Ear
Price Target
$51 -> $85
2025-05-15
maintain
Outperform
Reason
Mizuho
Uy Ear
Buy
Initiates
$51
2025-04-21
Reason
Mizuho
Uy Ear
Price Target
$51
2025-04-21
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tectonic Therapeutic Inc (TECX.O) is -4.21, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Tectonic Therapeutic Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.55
Current PE
-4.21
Overvalued PE
-3.48
Undervalued PE
-7.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.44
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.37
Undervalued EV/EBITDA
-1.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 215.5% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TECX News & Events

Events Timeline

(ET)
2025-11-06
16:09:12
Tectonic Therapeutics announces Q3 EPS of $1.02, below consensus estimate of $1.05
select
2025-09-02 (ET)
2025-09-02
15:11:42
Truist: Tectonic pullback on Eli Lilly's relaxin data is excessive
select
2025-06-30 (ET)
2025-06-30
08:21:36
Tectonic Therapeutic joins Russell 3000 Index
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-30NASDAQ.COM
TECX, GKOS, GH, ALGN, NMRA Experience After-Hours Surge Following Clinical Data and Earnings Reports

  • Tectonic Therapeutics Surge: Tectonic Therapeutic Inc. (TECX) saw a significant increase of 30.93% after announcing positive results from its Phase 1b trial of TX45 for pulmonary hypertension, improving heart function and hemodynamics.

  • Glaukos Corp. Performance: Glaukos Corp. (GKOS) rose 15.45% following a report of third-quarter net sales of $133.5 million, a 38% year-over-year increase, despite a net loss that improved from the previous year.

  • Guardant Health Gains: Guardant Health Inc. (GH) experienced a 19.29% increase in after-hours trading, reporting a 39% rise in third-quarter revenue to $265.2 million and narrowing its net loss compared to last year.

  • Align Technology Growth: Align Technology, Inc. (ALGN) shares jumped 15.15% after reporting a third-quarter net income of $56.8 million, with expectations for sequential revenue growth in the fourth quarter.

[object Object]
Preview
4.0
09-05TipRanks
Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%

  • Strong Buy Ratings: Three biotech stocks—Voyager Therapeutics, Tectonic Therapeutics, and Cullinan Management—are receiving "Strong Buy" ratings from analysts, indicating strong long-term growth potential in their respective markets.

  • Growth Projections: Voyager Therapeutics is projected to rise over 402%, Tectonic Therapeutics by 356%, and Cullinan Management by 316%, despite recent declines in their stock prices, highlighting significant upside potential if they successfully advance their pipelines.

[object Object]
Preview
4.0
09-04Benzinga
Oppenheimer Begins Coverage of Tectonic Therapeutics with Outperform Rating and Sets Price Target at $80

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to enhance their market strategies and decision-making.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to unique stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tectonic Therapeutic Inc (TECX) stock price today?

The current price of TECX is 20.98 USD — it has increased 3.76 % in the last trading day.

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s business?

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

arrow icon

What is the price predicton of TECX Stock?

Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is 85.00 USD with a low forecast of 76.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s revenue for the last quarter?

Tectonic Therapeutic Inc revenue for the last quarter amounts to -21.89M USD, increased 11.47 % YoY.

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s earnings per share (EPS) for the last quarter?

Tectonic Therapeutic Inc. EPS for the last quarter amounts to -17996000.00 USD, decreased -8.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tectonic Therapeutic Inc (TECX)'s fundamentals?

The market is revising No Change the revenue expectations for Tectonic Therapeutic, Inc. (TECX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 24.88%.
arrow icon

How many employees does Tectonic Therapeutic Inc (TECX). have?

Tectonic Therapeutic Inc (TECX) has 51 emplpoyees as of December 05 2025.

arrow icon

What is Tectonic Therapeutic Inc (TECX) market cap?

Today TECX has the market capitalization of 393.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free